GET DAILY SIGNALSGoodRx Holdings (GDRX) Q3 2026 Earnings: Watching the Revenue Transition
Key Takeaways
- GoodRx Holdings (GDRX) is expected to report its third-quarter 2026 results after the market close on Tuesday, November 3, 2026, with a conference call scheduled for the following morning.
- Wall Street consensus points to earnings of roughly $0.08 per share and revenue of about $202 million for the quarter, compared with $0.08 per share and $196.0 million in the year-ago period.
- Investors will focus on the momentum of Pharma Direct and subscription offerings, which have offset persistent declines in the legacy prescription-transactions business.
- The company recently disclosed that it will restate its 2026 financials after an understatement of Pharma Direct revenue, a development that adds a layer of uncertainty to the quarter.
- Monthly Active Consumers (MACs), a key engagement metric, fell 12% year over year to 5.0 million in the second quarter, reflecting a deliberate shift in strategy.
- For additional context, explore Major News, Today's Price Move, Price Targets, and Forecast on dedicated pages, and browse Trending AI Robots for additional market signals.
Earnings Context and Why It Matters
GoodRx is navigating a strategic pivot away from its traditional prescription-discount transaction model and toward higher-margin, more durable revenue streams, namely Pharma Direct and subscription plans. The third-quarter 2026 report is a critical checkpoint in that transition. In the second quarter, Pharma Direct revenue surged 76% year over year while subscription revenue rose 39%, even as prescription-transactions revenue declined 26%. Management has raised full-year guidance, signaling confidence that the newer businesses will more than offset a shrinking core. For investors, this report will show whether that rebalancing is progressing fast enough to return the company to overall revenue growth. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Earnings Expectations
Analysts expect GoodRx to post roughly $0.08 in earnings per share on approximately $202 million in revenue for the third quarter of 2026, which would mark modest revenue growth from the $196.0 million recorded a year earlier. The bar is set against a backdrop of mixed recent performance: the company has beaten consensus earnings-per-share estimates in only a handful of its recent quarters. Beyond the headline figures, investors will scrutinize Pharma Direct growth, subscription-plan additions, and the trajectory of Monthly Active Consumers. Management's full-year 2026 guidance calls for revenue of $790 million to $805 million and adjusted EBITDA (earnings before interest, taxes, depreciation, and amortization) of $240 million to $250 million, so any commentary on reaffirming or adjusting that range will be closely watched.
Market Reaction and Investor Sentiment
Sentiment heading into this report is cautious but attentive. GoodRx shares have been under pressure amid declining consumer engagement and a strategic shift that is still unfolding. A newly disclosed restatement of 2026 financials, tied to an understatement of Pharma Direct revenue under accounting rules, could weigh on investor confidence even if it reflects higher revenue than initially reported. Key risk factors include continued erosion of Monthly Active Consumers, pressure on prescription-transactions revenue, and execution risk as the company scales its subscription and Pharma Direct businesses. A print that shows stronger-than-expected growth in those newer segments could reassure the market, while any softness in engagement metrics may amplify concerns about the pace of the transition.
Forward Outlook and Key Factors to Monitor
Looking past the third-quarter report, investors should monitor whether Pharma Direct can sustain its rapid growth rate. This business has become GoodRx's primary growth engine, and management has signaled expectations for strong full-year expansion. Commentary on GLP-1 access programs and consumer-direct pricing relationships with pharmaceutical manufacturers will offer clues about the durability of that momentum.
Subscription momentum is another focal point. The company has been rolling out condition-specific plans and new offerings such as GoodRx Companion, and subscription-plan growth of 14% year over year in the second quarter suggests early traction. Whether that growth accelerates while the legacy prescription-transactions business stabilizes will shape the path back to overall revenue growth.
Finally, the restatement process and any disclosure around internal-control weaknesses deserve attention. The company expects to report material weaknesses in internal control over financial reporting and is working to file amended quarterly reports. Progress on resolving these matters, combined with any updates to full-year guidance, will be key factors in how investors assess the company's execution and financial reporting quality in the quarters ahead.
Using AI Tools in My Research Process
I often turn to Tickeron’s AI Screener when preparing for earnings like this one. It lets me quickly filter stocks by technical patterns, fundamentals, and AI signals, which helps put GoodRx’s metrics in better context without spending hours on manual checks. The tool has become a regular part of how I evaluate companies during reporting season.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
Aroon Indicator for GDRX shows an upward move is likely
GDRX's Aroon Indicator triggered a bullish signal on November 02, 2026. Tickeron's A.I.dvisor detected that the AroonUp green line is above 70 while the AroonDown red line is below 30. When the up indicator moves above 70 and the down indicator remains below 30, it is a sign that the stock could be setting up for a bullish move. Traders may want to buy the stock or look to buy calls options. A.I.dvisor looked at 147 similar instances where the Aroon Indicator showed a similar pattern. In 120 of the 147 cases, the stock moved higher in the days that followed. This puts the odds of a move higher at 82%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 08, 2026. You may want to consider a long position or call options on GDRX as a result. In 76 of 95 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 80%.
The Moving Average Convergence Divergence (MACD) for GDRX just turned positive on October 09, 2026. Looking at past instances where GDRX's MACD turned positive, the stock continued to rise in 38 of 48 cases over the following month. The odds of a continued upward trend are 79%.
GDRX moved above its 50-day moving average on October 20, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for GDRX crossed bullishly above the 50-day moving average on October 22, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 9 of 12 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 75%.
Following a +2.84% 3-day Advance, the price is estimated to grow further. Considering data from situations where GDRX advanced for three days, in 199 of 252 cases, the price rose further within the following month. The odds of a continued upward trend are 79%.
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 43 of 56 cases where GDRX's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 77%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where GDRX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 82%.
GDRX broke above its upper Bollinger Band on October 12, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 8 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 41 (best 1 - 100 worst), indicating steady price growth. GDRX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 85 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.838) is normal, around the industry mean (4.699). GDRX has a moderately high P/E Ratio (58.167) as compared to the industry average of (13.248). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.133). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (1.494) is also within normal values, averaging (6.065).
The Tickeron SMR rating for this company is 88 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. GDRX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 96, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry ServicestotheHealthIndustry
Advertisement